This study evaluated the effects of NPQ Plus supplementation on skin health, antioxidant status, fatigue, and self-perceived well-being in healthy adults with skin concerns. NPQ Plus is a multi-component nutraceutical formulation containing polyphenols (Oligonol®), nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex), which are known to possess antioxidant and cellular protective properties.

This was a single-arm, open-label, prospective interventional study involving 55 participants. Subjects consumed one sachet of NPQ Plus daily for 12 weeks. Assessments were performed at baseline and at Weeks 4, 8, and 12. Skin health was evaluated using the Patient-Oriented Eczema Measure (POEM), visual analogue scale (VAS), and objective skin biophysical measurements including skin elasticity, hydration, transepidermal water loss (TEWL), pigmentation, inflammation, and sebum secretion. Antioxidant status was assessed by measuring total antioxidant capacity (TAOC), malondialdehyde (MDA), 3-nitrotyrosine (3-NT), and 8-hydroxy-2'-deoxyguanosine (8-OHdG). Fatigue symptoms and self-perceived improvements in skin health, sleep quality, and overall well-being were also evaluated.

Skin aging is influenced by intrinsic aging processes and environmental stressors, including ultraviolet radiation, pollution, and oxidative stress. These factors contribute to impaired skin barrier function, reduced hydration and elasticity, inflammation, pigmentation changes, and increased oxidative damage to lipids, proteins, and DNA. Nutraceutical supplementation containing antioxidant and mitochondrial-supporting bioactive compounds has emerged as a potential strategy to mitigate these changes by enhancing endogenous antioxidant defenses and supporting cellular repair mechanisms.

NPQ Plus is a multi-component nutritional supplement comprising polyphenols (Oligonol®), nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex). These ingredients have been reported to possess antioxidant, anti-inflammatory, and mitochondrial-supportive properties that may improve skin condition, reduce oxidative stress, and alleviate fatigue.

This completed study employed a single-arm, open-label, prospective interventional design. Fifty-five healthy adults with skin concerns were enrolled and instructed to consume one sachet of NPQ Plus daily for 12 weeks. Clinical assessments were conducted at baseline and after 4, 8, and 12 weeks of supplementation.

The primary evaluations included objective skin biophysical measurements using the Multiprobe Adapter (MPA) system, consisting of skin elasticity (Cutometer®), skin hydration (Corneometer®), transepidermal water loss (Tewameter®), skin inflammation and pigmentation (Mexameter®), and sebum secretion (Sebumeter®). Patient-reported skin outcomes were assessed using the Patient-Oriented Eczema Measure (POEM), visual analogue scale (VAS), and self-perceived improvements in skin health.

Systemic antioxidant status and oxidative damage were evaluated using saliva biomarkers, including total antioxidant capacity (TAOC), malondialdehyde (MDA), 3-nitrotyrosine (3-NT), and 8-hydroxy-2'-deoxyguanosine (8-OHdG). Fatigue was assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale, while participants also reported changes in sleep quality and overall well-being.

The study aimed to characterize longitudinal changes following NPQ Plus supplementation across multiple domains, including skin health, antioxidant status, fatigue symptoms, and participant-reported outcomes, over the 12-week intervention period.

Inclusion Criteria:

• Experiencing at least one skin concern (e.g., itchiness, dryness, roughness, flaking, or skin cracking) within the previous 3 months.
• Willing and able to consume one sachet of NPQ Plus daily for 12 weeks.
• Willing to attend all scheduled study visits and assessments.
• Able to understand the study procedures and provide written informed consent.

Exclusion Criteria:

• Consumption of dietary supplements intended to improve skin health within the previous 3 months.
• Pregnant or breastfeeding women.
• Known allergy or hypersensitivity to any ingredient in NPQ Plus.
• Presence of any medical condition or concurrent medication that, in the opinion of the investigator, could interfere with study participation or outcome assessments.
• Participation in another clinical study within the previous 3 months.
• Unable or unwilling to comply with the study protocol.

Individual Participant Data (IPD) that underlie the published results, after de-identification, will be made available upon reasonable request to the Principal Investigator. Data sharing requests will be evaluated based on scientific merit, ethical considerations, and institutional approval.

Beginning 6 months after publication of the study results and ending 5 years after publication.

Qualified researchers may request access to de-identified individual participant data by submitting a written request to the Principal Investigator. Requests must include a research proposal outlining the intended use of the data. Access will be granted following review and approval by the Principal Investigator and the sponsoring institution, subject to applicable ethical and institutional data-sharing requirements.